Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction

Area of Science:

• Oncology
• Surgical Oncology
• Breast Cancer Research

Background:

• Molecular subtyping is crucial in breast cancer care.
• Breast cancer subtypes influence treatment decisions and prognosis.
• Understanding subtype-specific risks is vital for patient management.

Purpose of the Study:

• To determine the role of breast cancer subtyping in breast reconstruction.
• To assess if subtyping predicts the need for postmastectomy radiation therapy.
• To evaluate subtyping's impact on recurrence-free survival for reconstruction planning.

Main Methods:

• Review of prospectively collected data from 1931 reconstructed breasts (1999-2012).
• Classification of breasts by molecular subtype: Luminal A, Luminal B, Luminal HER2, HER2-enriched, Triple-Negative.
• Analysis of covariates predicting recurrence-free survival and need for postmastectomy radiation therapy.

Main Results:

• Distribution of subtypes: Luminal A (39%), Luminal B (27.9%), Luminal HER2 (11.6%), HER2-enriched (7.4%), Triple-Negative (13.8%).
• Postmastectomy radiation therapy rates varied significantly by subtype (p < 0.0001).
• Luminal A demonstrated superior recurrence-free survival; Triple-Negative showed worse outcomes compared to HER2-enriched.

Conclusions:

• This study is the first to use breast cancer subtype to stratify risk in breast reconstruction decisions.
• Subtyping can inform surgical planning for both immediate and delayed breast reconstructions.
• Risk stratification via subtyping optimizes treatment and reconstruction strategies.